+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Flat-Rate Subscription to La Merie Publishing Reports & News Services

  • ID: 3960374
  • Newsletter
  • March 2017
  • Region: Global
  • La Merie Publishing
1 of 2

A one-year subscription to this service provides access to:

  • all existing reports on stock and listed online in the store;
  • all new reports released by the publisher during the term of the subscription;
  • 12 (monthly) issues of three different R&D and Business Tracking services;
  • 50 (weekly) issues of R&D Pipeline News

Among the publisher's reports are:

  • Competitor Analysis reports in tabular presentation format;
  • Brief Reports and Full Reports.

A full listing of existing reports can be found in the online store. Publishing activities include updates of existing reports as well as release of new reports.

Among the News & Information Services are:

  • R&D and Business Tracker for TCR & CAR T-Cells and NK Cells;
  • R&D and Business Tracker for Bispecific Antibodies;
  • R&D and Business Tracker for Antibody-Drug Conjugates;
  • R&D Pipeline News - Technology Edition;
  • R&D Pipeline News - Therapeutic Area Edition.

After purchase of the Flat-Rate Subscription to La Merie Publishing Reports & News Services, credentials to access a dedicated server account with the report archive will be provided by e-mail. New issues of R&D Pipeline News and the R&D and Business Tracking Services will be delivered by e-mail, old issues are archived in the dedicated server account.

Coverage of the publishers reports:

The publisher has a special focus on biologics including, but not limited to:

  • Antibody-drug conjugates;
  • Bispecific antibodies including T-cell or NK cell redirecting antibodies
  • CAR & TCR engineered T-cells and NK cells;
  • Immuno-oncology;
  • Biosimilar antibodies and proteins
  • Biosuperior antibodies;
  • Therapeutic proteins;
  • Therapeutic and prophylactic vaccines;
  • Therapeutic peptides.

Reports of the Competitor Analysis Series deliver NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases and technologies provided in a tabular format and fully referenced.

Full Reports and Brief Reports provide in-depth description and analysis of targets, pipelines, companies and technologies.

Examples of Full Reports as of November 2016 are:

  • TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs        
  • T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals

Examples of Brief Reports as of November 2016 are:

  • CD22: a suitable antigen for targeted payload delivery by immunotherapeutics 
  • CD123: a paradigmatic target for immunotherapeutic treatment modalities        
  • RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists       

Examples of Competitor Analysis Reports as of November 2016 are:

  • Biosimilar and Biosuperior Therapeutic Antibodies
  • PD-1 and PD-L1 Immune Checkpoint Inhibitors 2016
  • Bispecific Antibodies for Cancer, Inflammatory & Other Diseases         
  • PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors

Examples of Vaccine Reports

  • Clostridium Difficile Vaccines and Therapeutics 2016
  • Flavivirus Vaccines: Zika, Dengue, Chikungunya, West Nile, Yellow Fever, Japanese Encephalitis & Tick-Borne Encephalitis Virus Vaccines

Examples of Peptide Reports:

  • Cancer Peptides       
  • Cardiometabolic Peptides   
  • Anti-Infective Peptides       
  • Cardiovascular Peptides
  • Anti-Inflammatory Peptides
Note: Product cover images may vary from those shown
2 of 2
Note: Product cover images may vary from those shown